抗淋巴细胞球蛋白在尸体肾移植中的临床经验。
Clinical experience with antilymphocyte-globulin in cadaveric kidney transplantation.
作者信息
Ahlmen J, Storm B, Brynger H, Sandberg L, Gelin L E
出版信息
Scand J Urol Nephrol Suppl. 1977(42):90-3.
Two different commercially available anti-lymphocyte-globulin preparations have been used in 30 recipients of primary cadaveric kidneys. No difference in graft survival was found within three years after transplantation compared to 102 primary cadaceric kidney recipients who only received basic immunosuppression. When only patients completing an intended ALG dosage were considered, the one-year graft survival was 65% compared to 52% in patients not receiving ALG. In this series of ALG treated patients no major benefits were found compared to the basic immunosuppressive regimen used at this transplantation centre.
两种不同的市售抗淋巴细胞球蛋白制剂被用于30例初次接受尸体肾移植的受者。与102例仅接受基础免疫抑制的初次尸体肾移植受者相比，移植后三年内移植物存活率无差异。仅考虑完成预定抗淋巴细胞球蛋白剂量的患者时，接受抗淋巴细胞球蛋白治疗的患者一年移植物存活率为65%，而未接受抗淋巴细胞球蛋白治疗的患者为52%。在这组接受抗淋巴细胞球蛋白治疗的患者中，与该移植中心使用的基础免疫抑制方案相比，未发现明显益处。
Zotero 插件